Treatment of cryptococcal meningitis in Peruvian AIDS patients using amphotericin B and fluconazole

J Infect. 2008 Sep;57(3):260-5. doi: 10.1016/j.jinf.2008.06.020. Epub 2008 Aug 15.

Abstract

Objectives: To describe the mycologic and clinical outcomes and factors associated with failure in Peruvian patients with AIDS-associated cryptococcal meningitis (CM) treated with amphotericin B deoxycholate (Amph B) followed by fluconazole.

Methods: Patients were treated with intravenous Amph B 0.7 mg/kg/day for 2 or 3 weeks followed by oral fluconazole 400mg/day for 7 or 8 weeks. Clinical and laboratory evaluations including cerebrospinal fluid (CSF) studies were performed at baseline and at weeks 2 and 10.

Results: The CSF cultures were negative in 25% and 68% of 47 patients at weeks 2 and 10, respectively. In the univariate analysis, baseline low body mass index (BMI), hyponatremia, low serum albumin, positive blood culture and CSF antigen titers >or=1024 were associated with a positive CSF culture at week 2. Baseline positive urine culture, positive blood culture, any positive extraneural culture and CSF opening pressure at week 2 >or=300 mm H2O were associated with a positive CSF culture at week 10. In the multivariate analysis no association was found.

Conclusions: Therapy with Amph B and fluconazole, combined with aggressive management of elevated intracranial pressure (ICP), results in low CSF sterilization rates at week 2 and acceptable CSF sterilization rates at week 10 when compared with other series.

MeSH terms

  • Acquired Immunodeficiency Syndrome / complications*
  • Adult
  • Amphotericin B / administration & dosage
  • Amphotericin B / therapeutic use*
  • Antifungal Agents / therapeutic use*
  • Blood / microbiology
  • Cerebrospinal Fluid / microbiology
  • Cryptococcus / isolation & purification
  • Female
  • Fluconazole / administration & dosage
  • Fluconazole / therapeutic use*
  • Humans
  • Intracranial Pressure
  • Male
  • Meningitis, Cryptococcal / drug therapy*
  • Peru
  • Risk Factors
  • Treatment Outcome
  • Urine / microbiology

Substances

  • Antifungal Agents
  • Amphotericin B
  • Fluconazole